相关实验视频

Updated: Feb 17, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

系统的可使用药物的全基因组孟德尔随机化确定了冠状动脉疾病的基因支持治疗标

Boteng Yan^1,2, Peijiang Pan³, Wenfu Tao⁴

¹Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.

Current medicinal chemistry

|February 15, 2026

概括

这项研究使用了门德尔的随机化来确定66个基因支持的冠状动脉疾病 (CAD) 治疗点. 像ERP29,MCL1,TNXB,MAPK3和TNF这样的关键基因对新的CAD治疗有希望.

科学领域:

遗传学是一个遗传学.
药理学药理学是指药理学的学科.
心血管医学心血管医学

背景情况:

冠状动脉疾病 (CAD) 是全球主要的死亡原因,治疗选择有限.
确定基因验证的治疗点对于开发有效的CAD疗法至关重要.

研究的目的:

通过使用孟德尔随机化 (MR) 来识别和优先考虑CAD的基因支持治疗点.
调查这些目标的潜在机制和对目标的影响.

主要方法:

一个由两个样本组成的MR框架分析了血液中cis-表达定量特征位点 (cis-eQTLs) 对CAD的因果作用.
施泰格过,贝叶斯协同定位和灵敏度分析整合了MR的发现.
调解和全现象MR分析探索了机制和基因效应.

主要成果:

在欧洲人群中确定了66个与CAD相关的因果性可用药物基因.
ERP29,MCL1,TNXB,DAGLB,FES和TRPM4与CAD共定位,并在东亚队列中复制.
MAPK3和TNF被强调为优先目标,调解分析揭示了与BMI,甘油三,血压和心房动的联系.

结论:

该研究验证了已知的CAD药物标,并发现了涉及血压和脂质代谢的新基因 (ERP29,MCL1,TNXB,DAGLB,FES,TRPM4).
作为可用药物的标,MAPK3和TNF显示出前景,可能为相关心脏代谢障碍带来好处.
需要进一步的研究来探索这些确定的目标的临床可行性和通用性.

关键词:

冠状动脉疾病是一种冠状动脉疾病.药物可用门德尔式随机化表达方式定量特征 loci.治疗目标是治疗的目标.

更多相关视频

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

In Vivo Modeling of the Morbid Human Genome using Danio rerio

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...